NRXS · Neuraxis, INC
$5.74
+0.05 (+0.88%)
At close · Sep 11
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Neither future cash generated from operating activities, nor management’s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$72.08M
Shares
12.56M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.74
Open$5.77
Day$5.65–5.77
52W close$2.31–8.81
Avg vol 30d79K
Short int249K · 2.0% float · 3.7d
Short vol57%
Last earningsAug 11, 2026
DataAug 2023–Sep 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 29, 2026
Est · unconfirmed
· in 11 wks
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$5.32M
Trailing 12 months
Net income (TTM)
−$7.68M
Trailing 12 months
Revenue growth YoY
+115.7%
Year over year
Operating margin
-144.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+42.2%
Year over year · more shares
Price change (1Y)
+133.2%
Trailing year
Short interest
2.0%
Latest settlement · 3.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−5%
below
Price vs 50-day avg
−12%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
53%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
−25%
trailing
YTD return
+26%
this year
Relative strength
−43%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+23% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.98% of float · ▼ -39.5% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
32 holders — near 3-yr high, broad support
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
+33%
Y/Y
Gross margin
84%
contracting
EPS growth
+22%
Y/Y
Free cash flow
$-6.5M
Balance sheet
$25.4K
net cash
Quant / Vol
risk profile
Volatility
73%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−5%
Neutral
Price vs 50-day avg
−12%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
53%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $6 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+23% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.98% of float · ▼ -39.5% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
32 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $6 · 53%
Range high $9
vs 200-day avg -5%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NRXS
this stock
Neuraxis, INC
|
$72.08M | +26.4% | +32.9% | — | 2.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NRXS | -5.4% | -8.6% | -24.7% | -4.5% | +26.4% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -4.3% | -6.9% | -42.5% | -4.1% | +14.4% |